Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
AIDS Research and Therapy
Published in: AIDS Research and Therapy 1/2018

Open Access 01-12-2018 | Research

A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV

Authors: Patrick G. Clay, Wei C. Yuet, Christiane H. Moecklinghoff, Inge Duchesne, Krzysztof L. Tronczyński, Sandip Shah, Dong Shao

Published in: AIDS Research and Therapy | Issue 1/2018

Login to get access

Abstract

Objectives

To compare outcomes with single tablet regimens (STR) versus multi-tablet regimens (MTR) for human immunodeficiency virus (HIV) treatment using published data.

Design

Systematic review and random-effects meta-analysis of literature on approved and investigational HIV regimens.

Methods

The research followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Single or un-blinded studies reporting a direct comparison between STR and MTR were eligible for the meta-analysis. Double-blinded studies were excluded due to lack of difference in pill burden between cohorts. The key outcomes of interest included: adherence rates/proportion meeting target, efficacy, safety/tolerability, non-clinical and economic outcomes.

Results

After screening 63 full-text articles and posters, 14 studies were eligible for the meta-analysis. The analysis showed that patients taking STR had improved outcomes over those taking MTR. Patients were significantly more adherent regardless of daily dosing frequency (odds ratio [OR]: 1.96, p < 0.001) and were more likely to achieve virological suppression (relative risk [RR]: 1.05, p = 0.002). There was a trend toward a lower discontinuation risk in the STR cohort, together with reported higher therapy satisfaction, better symptom control, improved health status, reduced healthcare resource utilization and demonstrated cost-effectiveness compared to MTR. There were no differences in CD4 cell count increase (at 48 weeks) or safety outcomes.

Conclusions

The findings of this study confirm previously reported preliminary findings of the advantages of STR over MTR for HIV treatment in adherence, therapy continuation, viral suppression, tolerability, quality of life improvement, cost-effectiveness and healthcare resource utilization.
Appendix
Available only for authorised users
Literature
1.
2.
U.S. Department of Health and Human Services. FDA approval of HIV medicines; 2016.
3.
U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2016.
4.
Centers for Disease Control and Prevention. Evolution of HIV/AIDS prevention programs–United States, 1981–2006. MMWR Morb Mortal Wkly Rep. 2006;55(21):597–603.
5.
6.
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2nd ed. Geneva: World Health Organization; 2016.
7.
World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.
8.
Deeks SG, Lewin SR, Havlir DV. The end of AIDS: hIV infection as a chronic disease. Lancet. 2013;382(9903):1525–33.CrossRef
9.
10.
U.S. Department of Health and Human Services. HIV/AIDS glossary: boosting; 2017.
11.
Clay PG, Nag S, Graham CM, Narayanan S. Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. Medicine (Baltimore). 2015;94(42):e1677.CrossRef
12.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.CrossRef
13.
Higgins JPT GS, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration 2008.
14.
Critical Appraisal Skills Programme (CASP). 12 questions to help you make sense of cohort study. 2017.
15.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRef
16.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRef
17.
Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV + homeless and marginally housed people. Aids. 2010;24(18):2835–40.CrossRef
18.
Fabbiani M, Zaccarelli M, Grima P, Prosperi M, Fanti I, Colafigli M, et al. Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naive or switching for simplification HIV-infected patients. BMC Infect Dis. 2014;14:26.CrossRef
19.
Skwara P, Bociaga-Jasik M, Kalinowska-Nowak A. Adherence to single-tablet versus multiple-tablet regimens in the treatment of HIV infection: a questionnaire-based survey on patients satisfaction. HIV AIDS Rev. 2014;13:95–9.CrossRef
20.
Sterrantino G, Santoro L, Bartolozzi D, Trotta M, Zaccarelli M. Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era. Patient Prefer Adherence. 2012;6:427–33.CrossRef
21.
Chen Y, Chen K, Kalichman SC. Barriers to HIV medication adherence as a function of regimen simplification. Ann Behav Med. 2017;51(1):67–78.CrossRef
22.
Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017;4(5):e195–204.CrossRef
23.
Sutton SS, Hardin JW, Bramley TJ, D’Souza AO, Bennet CL. Single-versus multiple tablet HIV regimens: adherence and hospitalization risks. Am J Manag Care. 2016;22:242–8.PubMed
24.
Buscher A, Hartman C, Kallen MA, Giordano TP. Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients. Int J STD AIDS. 2012;23(5):351–5.CrossRef
25.
Arribas JR, Pialoux G, Gathe J, Di Perri G, Reynes J, Tebas P, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis. 2014;14(7):581–9.CrossRef
26.
Pozniak A, Markowitz M, Mills A, Stellbrink HJ, Antela A, Domingo P, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis. 2014;14(7):590–9.CrossRef
27.
Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009;51(2):163–74.CrossRef
28.
Choi JY, Sungkanuparph S, Anekthananon T, Sax P, DeJesus E, Edelstein H, et al. Efficacy and safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian subjects with human immunodeficiency virus 1 infection: a sub-analysis of phase 3 clinical trials. Infect Chemother. 2016;48(3):219–24.CrossRef
29.
Rijnders B, Post F, Rieger A. Longer-term renal safety of tenofovir alafenamide vs tenofovir disoproxil fumarate. Conference on retroviruses and opportunistic infections, February 22–25, 2016, Boston 2016.
30.
Arribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl A, et al. A randomized, double-blind comparison of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil fumarate (TDF), each coformulated with Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: week 144 results. J Acquir Immune Defic Syndr 2017;75:211–8.CrossRef
31.
Koenig E, Orkin C, Clarke A, Podzamczer D, Clotet B, Callebaut C, et al. Improved safety and efficacy of TAF versus TDF single-tablet regimen in HIV-1 treatment-naïve women through week 48. J Int AIDS Soc. 2016;19(Suppl 1):21083.
32.
Palella FJ Jr, Fisher M, Tebas P, Gazzard B, Ruane P, Van Lunzen J, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. Aids. 2014;28(3):335–44.CrossRef
33.
Huhn GD, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, et al. A Randomized, Open-Label trial to evaluate switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in treatment-experienced HIV-1-infected adults. J Acquir Immune Defic Syndr. 2017;74(2):193–200.CrossRef
34.
Airoldi M, Zaccarelli M, Bisi L, Bini T, Antinori A, Mussini C, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4:115–25.PubMedPubMedCentral
35.
Hanna DB, Hessol NA, Golub ET, Cocohoba JM, Cohen MH, Levine AM, et al. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J Acquir Immune Defic Syndr. 2014;65(5):587–96.CrossRef
36.
Beck EJ, Mandalia S, Sangha R, Youle M, Brettle R, Gompels M, et al. Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004–2008. PLoS ONE. 2012;7(10):e47376.CrossRef
37.
Grimes RM, Shenouda TA. Using cost as a consideration for antiretroviral regimen selection: an example using average wholesale prices. AIDS Care. 2013;25(11):1380–4.CrossRef
38.
Homar F, Lozano V, Martinez-Gomez J, Oyaguez I, Pareja A, Payeras A, et al. Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs. Health Econ Rev. 2012;2(1):16.CrossRef
39.
Angeletti C, Pezzotti P, Antinori A, Mammone A, Navarra A, Orchi N, et al. Antiretroviral treatment based cost saving interventions may offset expenses for new patients and earlier treatment start. HIV Med. 2014;15:165–74.CrossRef
40.
Colombo GL, Castagna A, Di Matteo S, Galli L, Bruno G, Poli A, et al. Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. Ther Clin Risk Manag. 2014;10:9–15.PubMed
41.
Colombo GL, Di Matteo S, Antinori A, Medaglia M, Murachelli S, Rizzardini G. Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines. Clinicoecon Outcomes Res. 2013;5:489–96.CrossRef
42.
Colombo GL, Di Matteo S, Maggiolo F. Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen. Clinicoecon Outcomes Res. 2013;5:59–68.CrossRef
43.
Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013;158(2):84–92.CrossRef
44.
Sorbino-Jiménez C, Jiménez-Nácher I, Moreno-Ramos F. Analysis of antiretroviral therapy modification in routine clinical practice in the management of HIV infection. Eur J Hosp Pharm. 2017;24:96–100.CrossRef
45.
Sweet DE, Altice FL, Cohen CJ, Vandewalle B. Cost-effectiveness of single- versus generic multiple-tablet regimens for treatment of HIV-1 infection in the United States. PLoS ONE. 2016;11(1):e0147821.CrossRef
46.
Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open. 2013;3(8):e003028.CrossRef
47.
Juday T, Gupta S, Grimm K, Wagner S, Kim E. Factors associated with complete adherence to HIV combination antiretroviral therapy. HIV Clin Trials. 2011;12(2):71–8.CrossRef
Metadata
Title
A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV
Authors
Patrick G. Clay
Wei C. Yuet
Christiane H. Moecklinghoff
Inge Duchesne
Krzysztof L. Tronczyński
Sandip Shah
Dong Shao
Publication date
01-12-2018
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2018
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/s12981-018-0204-0

Other articles of this Issue 1/2018

AIDS Research and Therapy 1/2018 Go to the issue

Research

Prevalence of lower limb deep venous thrombosis among adult HIV positive patients attending an outpatient clinic at Mulago Hospital

Research

Factors associated with viral non-suppression among adolescents living with HIV in Cambodia: a cross-sectional study

Research

CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV

Research

Non-AIDS complexity amongst patients living with HIV in Sydney: risk factors and health outcomes

Research

Prognostic indicators in the World Health Organization’s algorithm for seriously ill HIV-infected inpatients with suspected tuberculosis

Review

Frailty in people living with HIV

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits